# BAY59-7939 Japanese in Atrial Fibrillation (2nd)

> **NCT00973323** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 100 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Xarelto (Rivaroxaban, BAY59-7939)
- **DRUG:** Xarelto (Rivaroxaban, BAY59-7939)
- **DRUG:** Xarelto (Rivaroxaban, BAY59-7939)
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT00973323
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2014-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00973323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00973323, "BAY59-7939 Japanese in Atrial Fibrillation (2nd)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00973323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*